Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI9447 · 1 trial · 1 indication
To assess the safety and tolerability, describe any dose-limiting toxicity (DLT) for MEDI9447
| Arm | Type | Description |
|---|---|---|
| MEDI9447 monotherapy | OTHER | Dose escalation of MEDI9447 monotherapy for patients with advanced solid malignancies |
| Name | Type | Description |
|---|---|---|
| MEDI9447 (oleclumab) | DRUG | MEDI9447 administered intravenously |
Major Inclusion Criteria: * Adult subjects; age ≥ 20 years * Has a histologically confirmed solid malignancy that is refractory to standard therapy or for which no standard of care regimen currently exists * Subjects must have at least 1 lesion that is measureable using RECIST v1.1 * All subjects m...
MEDI9447 is an investigational small molecule being developed for the treatment of advanced solid malignancies. It is currently in Phase 1 clinical development and has been studied in a completed trial involving patients with advanced solid tumors.
The specific molecular target of MEDI9447 has not been disclosed in available clinical trial information. The drug is being studied for its potential effects in advanced solid malignancies, but its mechanism of action is not publicly detailed.
MEDI9447 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical development for advanced solid malignancies.
MEDI9447 is in Phase 1 clinical development. It has completed one Phase 1 trial, and there are no active trials currently enrolling. The drug remains investigational and has not been approved by regulatory authorities.
MEDI9447 has been studied in one clinical trial, registered as NCT03736473. This was a Phase 1 study titled 'A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients,' which enrolled 6 participants with advanced solid malignancies. The trial has been completed.
Yes, MEDI9447 is also known as Oleclumab. In the clinical trial NCT03736473, the drug is referred to as MEDI9447 (Oleclumab), indicating that these names refer to the same investigational agent.